iCellate Medical secures 20 MSEK in new funding
Stockholm, Sweden – June 8, 2023 - iCellate Medical has closed a successful round of financing, raising 20 MSEK from a combination of existing and new investors. iCellate develops cancer tests for early detection, treatment selection, and hereditary cancer risk.iCellate is a privately held life sciences company, spearheading the industry in cancer profiling. Through liquid biopsy tests, the analysis of tumor-derived material in the blood or saliva, iCellate paves the way for precision medicine to reach more patients. Ongoing clinical studies investigating iCellate’s CTC-based technology,